Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P.; Hassel J.; Rutkowski P.; Baurain J.; Butler M.; Schlaak M.; Sullivan R.; Ochsenreither S.; Dummer R.; Kirkwood J.; Joshua A.; Sacco J.; Shoushtari A.; Orloff M.; Piulats J.; Milhem M.; Salama A.; Curti B.; Demidov L.; Gastaud L.; Mauch C.; Yushak M.; Carvajal R.; Hamid O.; Abdullah S.; Holland C.; Goodall H.; Piperno-Neumann S.

doi:10.1056/nejmoa2103485

← Today's brief

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan P. et al. · The New England journal of medicine · Friday, January 1, 2021

n 378Funding Independent

Source

Nathan P. et al.. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine. Friday, January 1, 2021.
doi:10.1056/nejmoa2103485Read original ↗

Generated, then checked against the source · how this brief was built →

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.